semaglutide cardiovascular outcomes 2025 news today 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Semaglutide currently not cost-effective for

Dont forget to explore our quick-access supplements like GLP-1 Daily Support and Weight Loss Boost to enhance your journey every step of the way

Many people have achieved long-term weight loss with Ozempic when combined with lifestyle changes

For comprehensive resources and the latest research, visit Diabetes in Control

Telehealth appointments may be available when clinically appropriate

Cravings for high-calorie foods decreased, and the constant background noise of hunger faded

launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage